Business
Grant of Warrants
Grant of Warrants.
About this update from Nuformix Plc
[{"type":"text","content":"\n \nRNS Number : 4909Y Nuformix PLC 06 December 2017 \n\nNuformix plc\n(\"Nuformix\" or \"the Company\")\n \nGrant of Warrants at 6p per share\n \nNuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces that Warrants over new ordinary shares have been granted to Beaufort Securities Limited, and have vested in accordance with the terms agreed with its recent appointment as the Company's broker:\n \n\n\n\n\nWarrants over no. of shares\n\n\nExercise price per share\n\n\nLapse date\n\n\n\n\n1,000,000\n\n\n6 pence\n\n\n20 November 2020\n\n\n\n\n \nFollow Nuformix on Vox Markets: follow at www.voxmarkets.co.uk/company/NFX\nand www.nuformix.com\n \nMarket Abuse Regulation (MAR) Disclosure. Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the publication of this announcement via a Regulatory Information Service and accordingly, this inside information is now considered to be in the public domain.\n \nENDS\n \nEnquiries:\n\n\n\n\nNuformix plc\nDan Gooding, Chief Executive Officer\n\n\n+44 (0)1223 423667\n \n\n\n\n\nBeaufort Securities Limited (Joint Broker)\nJon Belliss\n\n\n+44 (0)20 7382 8300\n \n\n\n\n\nGable Communications Ltd\nJohn Bick / Justine James\n\n\n+44 (0)20 7193 7463\n \n\n\n\n\n \nAbout Nuformix plc www.nuformix.com \nNuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules. \n \nNuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.\n \nNuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yield...